HWHan Min Woo

Han Min Woo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Han Min Woo has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Biofoundry Architect 1.0: A Robot-Assisted Module Configurator and Workflow Designer with Hub Interoperability and Throughput-Workflow Economic Evaluation

    by Jun Sung Park, Yu Been Heo, Han Min Woo

    Laboratory automation has rapidly advanced across chemistry, materials science, and the life sciences, enabling high-throughput and predictive experimentation. In synthetic biology, biofoundries facilitate Design−Build−Test−Learn cycles through automated workflows but remain limited by software tools lacking integration and throughput-workflow economic evaluation. Here, we present Biofoundry Architect 1.0, an open, web-based platform for designing, evaluating, and comparing automated workflows using robot-assisted modules (RAMs). The system enables quantitative assessment of performance metrics, including the turnaround time and cost, while ensuring workflow compatibility and scalability. By supporting modular design, interoperability, and community-based sharing of workflows, Biofoundry Architect bridges the gap between planning and execution, improving efficiency, accessibility, and collaborative innovation in laboratory automation. This web-based Biofoundry Architect software can be viewed at https://biofoundry-architect.streamlit.app/, and all code is released under the license GNU General Public License version 3.

  • Techno-economic assessment-guided biofoundry for microbial strain development

    by Yu Been Heo, Sung Cheon Ko, Jay D. Keasling, Han Min Woo


  • Open Access

    CRISPRi-assisted metabolic engineering of cyanobacteria for photosynthetic hyaluronic acid from CO2

    by Jigyeong Son, Hyun Jeong Lee, Han Min Woo

    Hyaluronic acid (HA) is widely used in pharmaceuticals, medicine, and cosmetics. Sustainable production has shifted to microbial fermentation using engineered GRAS strains. Diverse carbon sources and CO2 conversion via engineered microorganisms enhance HA production. Herein we applied advances in CRISPR technologies and tools to optimize metabolic pathway by redirecting carbon portioning in cyanobacterium Synechoccous elongatus PCC 7942, demonstrating enhanced HA production. S. elongatus PCC 7942 lacking hyaluronan synthase (HAS) required pathway engineering for HA production. By expressing heterologous Class I HAS, a modular gene expression system was employed, incorporating hasB and hasC for the HA-GlcA module and glmU, glmM, and glmS for the GlcNAc module. This approach resulted in construction of four engineered cyanobacterial strains. Optimizing metabolic pathway involving the HA-GlcA and GlcNAc modules led to SeHA220 (wild-type with HA-GlcA and GlcNAc modules) producing 2.4 ± 0.85 mg/L HA at 21 d, a 27.5-fold increase compared to the control. Targeting F6P and G6P metabolic nodes via CRISPR interference to repress zwf and pfk genes further improved production, with SeHA226 (SeHA220 with a gene repression module) achieving 5.0 ± 0.3 mg/L HA from CO2 at 15 d. Notably, SeHA226 produced photosynthetic HA with a molecular weight (Mw) of 4.2 MDa, comparable to native producers, emphasizing the importance of precursor balance and growth conditions. This study engineered cyanobacteria for efficient HA biosynthesis using modular gene expression and CRISPR-interference systems. Optimizing heterologous metabolic pathway was key to achieving high-molecular-weight photosynthetic HA production from CO2. The findings provide insights into tunable HA production, with future efforts aimed at scaling up photosynthetic HA production for larger-scale applications.


  • Open Access

    Bacterial biosynthesis of abietane-type diterpene ferruginol from glucose

    by Hyun Jeong Lee, Chaeyeon Kim, Yu Been Heo, Seong-Eun Kim, Han Min Woo

    Microbial supply of plant extracts is a promising biomanufacturing strategy that requires engineering of metabolic pathways and enzymes. This study presents the engineering of Corynebacterium glutamicum for heterologous production of diterpenes miltiradiene and ferruginol. Through targeted metabolic pathway modifications, including inactivation of pyruvate carboxylase and phytoene synthase, the HL01 strain was optimized to enhance pyruvate and geranylgeranyl pyrophosphate (GGPP) pools. Overexpression of key MEP pathway enzymes (Dxs and Idi) and implementation of three GGPP synthase modules further boosted diterpene synthesis. Then, combining those modules with diterpene synthase (DiTPS) and intact P450 reductase modules (CYP76AH1 and CPR1) enabled production of miltiradiene (ferruginol equivalent) at 237.46 ± 34.8 mg/L and ferruginol at 107.34 ± 1.2 mg/L under constant glucose feeding, respectively. Modular gene expression for heterologous metabolic pathway can be optimized for bacterial biosynthesis. This is the first demonstration of ferruginol production in bacteria. These findings pave the way for further optimization of diterpene biosynthesis through pathway engineering and module integration in bacterial systems.


  • Open Access

    CRISPR–dCas13a system for programmable small RNAs and polycistronic mRNA repression in bacteria

    by Sung Cheon Ko, Han Min Woo

    Bacterial small RNAs (sRNAs) function in post-transcriptional regulatory responses to environmental changes. However, the lack of eukaryotic RNA interference-like machinery in bacteria has limited the systematic engineering of RNA repression. Here, we report the development of clustered regularly interspaced short palindromic repeats (CRISPR)-guided dead CRIPSR-associated protein 13a (dCas13a) ribonucleoprotein that utilizes programmable CRISPR RNAs (crRNAs) to repress trans-acting and cis-acting sRNA as the target, altering regulatory mechanisms and stress-related phenotypes. In addition, we implemented a modular loop engineering of the crRNA to promote modular repression of the target gene with 92% knockdown efficiency and a single base-pair mismatch specificity. With the engineered crRNAs, we achieved targetable single-gene repression in the polycistronic operon. For metabolic application, 102 crRNAs were constructed in the biofoundry and used for screening novel knockdown sRNA targets to improve lycopene (colored antioxidant) production in Escherichia coli. The CRISPR–dCas13a system will assist as a valuable systematic tool for the discovery of novel sRNAs and the fine-tuning of bacterial RNA repression in both scientific and industrial applications.


  • Cytosine base editing in cyanobacteria by repressing archaic Type IV uracil‐DNA glycosylase

    by Mieun Lee, Yu Been Heo, Han Min Woo

    SUMMARY: Base editing enables precise gene editing without requiring donor DNA or double‐stranded breaks. To facilitate base editing tools, a uracil DNA glycosylase inhibitor (UGI) was fused to cytidine deaminase‐Cas nickase to inhibit uracil DNA glycosylase (UDG). Herein, we revealed that the bacteriophage PBS2‐derived UGI of the cytosine base editor (CBE) could not inhibit archaic Type IV UDG in oligoploid cyanobacteria. To overcome the limitation of the CBE, dCas12a‐assisted gene repression of the udg allowed base editing at the desired targets with up to 100% mutation frequencies, and yielded correct phenotypes of desired mutants in cyanobacteria. Compared with the original CBE (BE3), base editing was analyzed within a broader C4–C16 window with a strong TC‐motif preference. Using multiplexed CyanoCBE, while udg was repressed, simultaneous base editing at two different sites was achieved with lower mutation frequencies than single CBE. Our discovery of a Type IV UDG that is not inhibited by the UGI of the CBE in cyanobacteria and the development of dCas12a‐mediated base editing should facilitate the application of base editing not only in cyanobacteria, but also in archaea and green algae that possess Type IV UDGs. We revealed the bacteriophage‐derived UGI of the base editor did not repress Type IV UDG in cyanobacteria. To overcome the limitation, orthogonal dCas12a interference was successfully applied to repress the UDG gene expression in cyanobacteria during base editing occurred, yielding a premature translational termination at desired targets. This study will open a new opportunity to perform base editing with Type IV UDGs in archaea and green algae.